KEYSTONE, Colo.--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced findings from a phase I study of ZIO-101, a proprietary organic arsenic, showed that 43 percent of relapsing, progressing multiple myeloma patients experienced stable disease and that the drug was well tolerated in all 14 patients in the study group. There was no clinically significant bone marrow suppression in patients with either prior or no prior transplant. The patients in the study group had failed a median of eight prior treatments. Dr. Mohamad Hussein of the Moffitt Cancer Center and colleagues presented the findings at the Bone Marrow Transplant Tandem meetings being held in Keystone, Colorado. These data suggest that ZIO-101 may be active in myeloma, and may also be useful in patients who suffer a disease relapse post-bone marrow transplant.
